Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) therapeutic targeting adipose-specific gene expression to combat obesity. The Phase 1/2a study, AROALK7-1001, recently dosed its first participants. In addition to a single agent, the study will employ combination approaches using tirzepatide in obese individuals, including those with type 2 diabetes.
A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab.
ARO-ALK7 marks a significant step for the California-based biotech company. Arrowhead Pharmaceuticals, Inc. has gained recognition for its TRiM™ platform, which delivers siRNA to multiple tissue types. This platform supports the company’s broader RNAi pipeline, including ARO-INHBE, its second obesity-targeted therapy in clinical development.
Dr. James Hamilton, Chief Medical Officer and R&D Head, made the following comment:
“Both programs have strong genetic validation and promising results in preclinical studies, which suggest that silencing the respective genes may lead to reduced body weight and potentially preserve lean muscle mass resulting in improved body composition.”
The significant purpose of the trial is to evaluate the investigational drug’s ability to suppress ACVR1C gene activity in adipose tissue, possibly improving body composition as well as reducing metabolic risks.
Around the time of the announcement, a cautious optimism was reflected in the stock’s performance as the price went up by 15.69% in the last month while the six-month insider ownership declined by 2.90%. On May 20, 2025, HC Wainwright & Co. reaffirmed its Buy rating and maintained an $80 price target.
With a modest weekly performance uptick of 4.42% and Arrowhead Pharmaceuticals, Inc. launching a clinical trial on its drug, the stock might see an update in analyst estimates soon.
READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds
Hedge Fund Resource Center